TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Neurosense Therapeutics Ltd. ( (NRSN) ) is now available.
NeuroSense Therapeutics Ltd. recently completed a pre-New Drug Submission meeting with Health Canada to discuss the potential early approval of its ALS treatment, PrimeC, under the expedited Notice of Compliance with Conditions pathway. The meeting was constructive, and the company is awaiting formal notification on its eligibility to proceed, which could significantly impact its market positioning and operations.
The most recent analyst rating on (NRSN) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.
Spark’s Take on NRSN Stock
According to Spark, TipRanks’ AI Analyst, NRSN is a Underperform.
Neurosense Therapeutics Ltd. faces substantial financial difficulties, including no revenue and negative equity, severely impacting its overall score. Technical indicators are neutral but do not offset financial weaknesses. The valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on NRSN stock, click here.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. operates in the biotechnology industry, focusing on developing treatments for neurodegenerative diseases. The company’s primary product is PrimeC, which is aimed at treating Amyotrophic Lateral Sclerosis (ALS).
Average Trading Volume: 261,385
Technical Sentiment Signal: Buy
Current Market Cap: $52.78M
For an in-depth examination of NRSN stock, go to TipRanks’ Overview page.